Medicine
Annovera 17.4 mg/103 mg vaginal ring
Annovera 17.4 mg/103 mg vaginal ring is a prescription medicine containing Ethinyl estradiol and Segesterone for vaginal use, marketed by Mayne Pharma, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Do not refrigerate or freeze and avoid excessive heat. Conditions Prior to…
Key facts
- Active ingredient (INN)
- Ethinyl estradiol and Segesterone
- Brand
- Annovera
- Strength
- 17.4 mg/103 mg
- Dosage form
- Vaginal ring
- Route
- Vaginal
- Packs
- 1 pouch
- Marketing authorisation holder
- Mayne Pharma
- Manufacturer
- Mayne Pharma
- Origin register
- US FDA, United States
- Storage
- Do not refrigerate or freeze and avoid excessive heat. Conditions Prior to dispensing ANNOVERA to the user, store ANNOVERA at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.39Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 16 August 2024
- Identifiers
- RxCUI 2055983, 2055989DailyMed set ID eb18194f-2021-41fa-8bdf-31e0c0eb646bNDC 68308-752Application NDA209627
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 pouch in 1 carton / 30 ring in 1 pouch | 68308-752-01 | Mayne Pharma | 16 August 2024 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 10 August 2018 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Ethinyl estradiol and Segesterone is a fixed-dose combination of an estrogen and a progestin indicated by females of reproductive potential to prevent pregnancy. It is available as vaginal rings. MedsAcross supplies Ethinyl estradiol and Segesterone for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Ethinyl estradiol and SegesteroneFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Annovera prescribing information (Mayne Pharma) · U.S. National Library of Medicine, DailyMed
Need Annovera 17.4 mg/103 mg vaginal ring for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.